Pharvaris Future Growth
Future criteria checks 0/6
Pharvaris is forecast to grow earnings and revenue by 31.1% and 67.7% per annum respectively. EPS is expected to grow by 32.7% per annum. Return on equity is forecast to be -93.9% in 3 years.
Key information
31.1%
Earnings growth rate
32.7%
EPS growth rate
| Pharmaceuticals earnings growth | 19.8% |
| Revenue growth rate | 67.7% |
| Future return on equity | -93.9% |
| Analyst coverage | Low |
| Last updated | 20 Jan 2025 |
Recent future growth updates
No updates
Recent updates
Pharvaris: Despite 30% Decline, Still Fair At Best
Dec 29Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation
Dec 02
We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Aug 16Pharvaris: Digging Deep For Sufficient Market Size
Jan 17We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Oct 09Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
May 13Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth
Jan 11We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Sep 26Pharvaris GAAP EPS of -€0.38
Sep 12Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
Aug 22We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Jun 08Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Dec 21We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Aug 25Pharvaris reports Q1 results
May 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 42 | -159 | -176 | -158 | 3 |
| 12/31/2026 | 2 | -180 | -190 | -168 | 5 |
| 12/31/2025 | N/A | -161 | -165 | -142 | 4 |
| 12/31/2024 | N/A | -138 | -133 | -116 | 4 |
| 9/30/2024 | N/A | -132 | -109 | -109 | N/A |
| 6/30/2024 | N/A | -114 | -99 | -99 | N/A |
| 3/31/2024 | N/A | -106 | -92 | -92 | N/A |
| 12/31/2023 | N/A | -101 | -93 | -93 | N/A |
| 9/30/2023 | N/A | -107 | -90 | -90 | N/A |
| 6/30/2023 | N/A | -92 | -81 | -81 | N/A |
| 3/31/2023 | N/A | -83 | -75 | -74 | N/A |
| 12/31/2022 | N/A | -76 | -67 | -67 | N/A |
| 9/30/2022 | N/A | -49 | -59 | -59 | N/A |
| 6/30/2022 | N/A | -50 | -54 | -54 | N/A |
| 3/31/2022 | N/A | -53 | -52 | -52 | N/A |
| 12/31/2021 | N/A | -43 | -45 | -45 | N/A |
| 9/30/2021 | N/A | -41 | -41 | -41 | N/A |
| 6/30/2021 | N/A | -38 | -38 | -38 | N/A |
| 3/31/2021 | N/A | -29 | -29 | -29 | N/A |
| 12/31/2020 | N/A | -26 | -22 | -21 | N/A |
| 9/30/2020 | N/A | -19 | -16 | -16 | N/A |
| 12/31/2019 | N/A | -8 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHVS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PHVS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PHVS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PHVS is forecast to have no revenue next year.
High Growth Revenue: PHVS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHVS is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/03 17:18 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharvaris N.V. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Alexandru Cogut | Bryan Garnier & Co |
| Jonathan Wolleben | JMP Securities |